Limits...
Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.

Jelinek GA, Weiland TJ, Hadgkiss EJ, Marck CH, Pereira N, van der Meer DM - Neurol. Res. (2015)

Bottom Line: Use of DMDs was not consistently associated with HRQOL.Individually, glatiramer acetate was associated with better HRQOL when compared with other DMDs or no DMD use.Glatiramer acetate had associations with better HRQOL compared with other DMDs.

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: To examine associations between medication use and health-related quality of life (HRQOL), relapse rate and disability in an international cohort of people with multiple sclerosis (PwMS).

Methods: Using Web 2.0 platforms, the authors recruited PwMS who completed survey items on demographics, medication use, HRQOL, relapse rate and disability.

Results: Of 2276 respondents from 56 countries, approximately half were taking a disease-modifying drug (DMD), most commonly glatiramer acetate or an interferon. Use of DMDs was not consistently associated with HRQOL. Individually, glatiramer acetate was associated with better HRQOL when compared with other DMDs or no DMD use. Overall, DMD use was neither associated with disability nor lower relapse rate, although those taking a DMD >12 months had 23.9% fewer relapses than those not taking a DMD. Polypharmacy, defined as those taking five or more over the counter, prescription or herbal medications, irrespective of DMD use, was associated with markedly worse HRQOL across all domains.

Discussion: There was no consistent association of DMD use with better health outcomes in this large international \sample of PwMS, although relapse rate appears lower for those taking a DMD for >12 months. Glatiramer acetate had associations with better HRQOL compared with other DMDs.

No MeSH data available.


Related in: MedlinePlus

Health-related quality of life (HRQOL) for low-dose naltrexone (LDN), all other DMDs and no DMD use*
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4507477&req=5

fig2: Health-related quality of life (HRQOL) for low-dose naltrexone (LDN), all other DMDs and no DMD use*

Mentions: Low-dose naltrexone was frequently being used in addition to one of the first or second generation DMDs. Of 163 people taking LDN, 32 were also taking glatiramer, 9 interferons, 4 fingolimod, 2 dimethyl fumarate, 2 natalizumab, 1 teriflunomide and 1 alemtuzumab. In addition, eight people taking LDN were also taking minocycline. The HRQOL for LDN was significantly lower across many domains than for those taking ‘other DMDs’ and those not taking DMDs (Fig. 2).


Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.

Jelinek GA, Weiland TJ, Hadgkiss EJ, Marck CH, Pereira N, van der Meer DM - Neurol. Res. (2015)

Health-related quality of life (HRQOL) for low-dose naltrexone (LDN), all other DMDs and no DMD use*
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4507477&req=5

fig2: Health-related quality of life (HRQOL) for low-dose naltrexone (LDN), all other DMDs and no DMD use*
Mentions: Low-dose naltrexone was frequently being used in addition to one of the first or second generation DMDs. Of 163 people taking LDN, 32 were also taking glatiramer, 9 interferons, 4 fingolimod, 2 dimethyl fumarate, 2 natalizumab, 1 teriflunomide and 1 alemtuzumab. In addition, eight people taking LDN were also taking minocycline. The HRQOL for LDN was significantly lower across many domains than for those taking ‘other DMDs’ and those not taking DMDs (Fig. 2).

Bottom Line: Use of DMDs was not consistently associated with HRQOL.Individually, glatiramer acetate was associated with better HRQOL when compared with other DMDs or no DMD use.Glatiramer acetate had associations with better HRQOL compared with other DMDs.

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: To examine associations between medication use and health-related quality of life (HRQOL), relapse rate and disability in an international cohort of people with multiple sclerosis (PwMS).

Methods: Using Web 2.0 platforms, the authors recruited PwMS who completed survey items on demographics, medication use, HRQOL, relapse rate and disability.

Results: Of 2276 respondents from 56 countries, approximately half were taking a disease-modifying drug (DMD), most commonly glatiramer acetate or an interferon. Use of DMDs was not consistently associated with HRQOL. Individually, glatiramer acetate was associated with better HRQOL when compared with other DMDs or no DMD use. Overall, DMD use was neither associated with disability nor lower relapse rate, although those taking a DMD >12 months had 23.9% fewer relapses than those not taking a DMD. Polypharmacy, defined as those taking five or more over the counter, prescription or herbal medications, irrespective of DMD use, was associated with markedly worse HRQOL across all domains.

Discussion: There was no consistent association of DMD use with better health outcomes in this large international \sample of PwMS, although relapse rate appears lower for those taking a DMD for >12 months. Glatiramer acetate had associations with better HRQOL compared with other DMDs.

No MeSH data available.


Related in: MedlinePlus